InvestorsHub Logo
Followers 18
Posts 2085
Boards Moderated 1
Alias Born 03/14/2008

Re: None

Monday, 11/28/2022 2:39:33 PM

Monday, November 28, 2022 2:39:33 PM

Post# of 54907
HLTT, pred's partner in wound care, posted its 10Q last month. 776k sales of pred's allograft in September. Looks good.

"Sales of our wound care allografts commenced in September 2022, as we delivered allografts to five customers for an aggregate purchase price, net of discounts, of $776,221. Payments for the sales did not commence until October, so we recorded accounts receivable from the sales of $720,777, representing the net sales revenue less an allowance for doubtful accounts of $55,444. After recording $51,834 in cost of goods sold (i.e. proportionate allocation to the products sold of the direct costs attributable to their production), we recorded gross profit of $720,175 for the three and nine months ended September 30, 2022. We expect that in future periods our gross margin ratio will be lower than the ratio we recorded in the periods ended September 30, 2022."

https://www.otcmarkets.com/filing/html?id=16221949&guid=xrG-kWHM7TC6dth